Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

CorNeat Vision Completes Pre-clinical Phase For Synthetic Cornea and Scleral Patch

This image opens in the lightbox

News provided by

CorNeat Vision

09 Sep, 2019, 12:05 GMT

Share this article

Share toX

Share this article

Share toX

- Innovative synthetic biology implants to be showcased at the 37th Congress of the ESCRS 2019 Paris

TEL AVIV, Israel, Sept. 9, 2019 /PRNewswire/ -- CorNeat Vision, an Israeli ophthalmic medical solution company, announced today it has completed the pre-clinical stage of its revolutionary cornea implant (CorNeat KPro / Keratoprosthesis) and the first synthetic, non-degradable scleral patch (CorNeat EverPatch). The company's solutions, which also include a revolutionary glaucoma drainage device, the CorNeat eShunt, will be showcased for the first time at the 37th Congress of the ESCRS (European Society of Cataract and Refractive Surgeons) in Paris, France on September 14th-18th, 2019.

CorNeat's synthetic biology technology enables its ophthalmic implants to completely and permanently integrate with surrounding tissue. This is done using a synthetic and non-degradable extra cellular matrix (ECM) that provides structural support to surrounding cells and stimulates their growth and proliferation into the implants. CorNeat Vision's pre-clinical trials, which included several animal ocular implantation studies, proved the safety of its technology as it applied to its synthetic cornea (CorNeat KPro), synthetic scleral patch (EverPatch) and glaucoma shunt (eShunt).

At the 37th Congress of the ESCRS (European Society of Cataract and Refractive Surgeons) CorNeat Vision will be showcasing the following products:

  • CorNeat KPro: A penetrating (full thickness) cornea implant which leverages synthetic biology to integrate a wide aperture synthetic optics within resident ocular tissue. Unlike corneal transplants and previous attempts to develop an artificial solution that are sutured or attempted integration with the native corneal tissue – a tissue that lacks blood vessels and heals very poorly; the CorNeat KPro, following a relatively simple, 30-45 minute implantation, permanently integrates with the eye wall under the conjunctiva, a site that heals much faster allowing firm durable integration. The CorNeat KPro provides an aesthetic, efficient, scalable remedy for millions of people with cornea-related visual impairments and is far superior to any available alternatives. CorNeat KPro is 100% synthetic and its implantation does not require the use of donor cornea tissue.
  • CorNeat EverPatch: The CorNeat EverPatch (scleral patch) is the first inert, synthetic and non-degradable tissue substitute for use in ophthalmic surgeries. CorNeat EverPatch replaces the use of human tissue and degradable collagen patches for covering and concealing implants such as glaucoma drainage devices and sealing the eye in cases of missing tissue. 
  • CorNeat eShunt: The first bio-integrating shunt that leverages non-degradable nanofibers that mimic the trabecular mesh to automatically regulate the intraocular pressure. CorNeat eShunt introduces long term efficacy and avoids clogging by draining deep in the orbit, in the intraconal space.

"We couple innovative ideas and tissue integration capability to create solutions serving to replace damaged biological organs and tissue or repair their function," noted Almog Aley-Raz, CorNeat CEO & VP R&D. "We are excited to have completed the pre-clinical trial phase with our first two products – the CorNeat KPro and CorNeat EverPatch – and are looking forward to the initiation and successful completion of clinical trials. We invite all interested ophthalmologists and potential business partners to visit the CorNeat Vision booth #D134 at the 37th Congress of ESCRS in Paris to hear about our solutions, view the CorNeat KPro surgery movie which will be presented at the event's video awards session, and learn more about our successful animal study featured in the Congress' Poster Village."

"CorNeat Vision brings new materials, ideas, and surgical techniques to the ophthalmic practice that address unmet needs," added Prof. Ehud Assia M.D., Director of the Center for Applied Eye Research at Israel's Meir Hospital and Medical Director of the Ein Tal Eye Center, a serial ophthalmic innovator and the 37th Congress of the ESCRS keynote speaker (Binkhorst Medal Lecture), and Chairman of CorNeat Vision's Advisory Board. "The results obtained by the CorNeat Vision team led by their Chief Medical Officer, Dr. Gilad Litvin, in the pre-clinical studies are extremely promising. I look forward to the clinical trials of the CorNeat EverPatch and the CorNeat KPro and trust that the studies, planned with leading colleagues in Israel, US, Canada, France, and China, will prove their high safety profile and demonstrate the superior efficacy of these two innovations."

About CorNeat Vision

CorNeat Vision is an ophthalmic medical device company with an overarching mission of improving health, sustainability and equality worldwide. CorNeat Vision was the 1st prize winner of China's (Shenzhen) Innovation Award in 2018 and was nominated as the 2018 BioMed Startup of the Year by the Israeli Innovation Authority. CorNeat Vision produces a lineup of innovative, safe, affordable and long-lasting ophthalmic medical solutions, including the CorNeat KPro, the CorNeat EverPatch and the CorNeat eShunt. Our products will significantly impact ophthalmic surgery practices in the areas of cornea, sclera, glaucoma and more. We are working relentlessly to significantly improve the well-being, quality of life, and general independence of blind and visually impaired people by offering innovative, permanent, convenient and affordable solutions which either replace the damaged organ or tissue or halt or prevent disease progression and, in some indications, enable regaining sight. For more information on CorNeat Vision and its solutions, visit us at www.corneat.com

Logo - https://mma.prnewswire.com/media/972196/CorNeat_Logo.jpg

Related Links

https://www.corneat.com/

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.